- Trial phase
- Phase 1/2 (completed)
- Time to market
- Years away. MW005 has completed Phase 1/2 testing but has no disclosed Phase 2/3 trial start or regulatory pathway, making any timeline to potential approval speculative and likely several years off if development proceeds.
- Why 2/10
- MW005 has no hard dated catalyst (PDUFA, pivotal readout, or Advisory Committee) scheduled in the next 12 months. The Phase 1/2 study concluded in 2023 with positive results, but no next-phase trial start or regulatory milestone has been announced. The drug is a small part of MediWound's pipeline behind commercial NexoBrid and Phase 3 EscharEx, so impactScore is low.
MW005 has no scheduled regulatory or pivotal-readout catalyst in the next 12 months. The next company-wide event is Q3 2026 earnings on November 12, 2026, but that is a financial update, not a drug-specific binary. Watch for any announcement from MediWound on next-phase development plans for MW005, which would be the first signal of meaningful pipeline progression.
Price Chart
Executive Summary
MW005 is a topical biologic gel in development by MediWound Ltd. (Nasdaq: MDWD) for low-risk Basal Cell Carcinoma (BCC), the most common form of skin cancer. It uses proteolytic enzymes (bromelain from pineapple stems) to digest cancerous tissue, offering a potential non-surgical alternative to excision. A Phase 1/2 study completed in 2023 showed positive results with complete clinical and histological clearance of target lesions and a good safety profile. However, MW005 is an early-stage asset with no disclosed next-phase trial or regulatory milestone, and it is a small part of MediWound's pipeline behind the approved NexoBrid burn treatment and the Phase 3 EscharEx wound-care program. The stock recently completed a $17.25M offering at $12.50/share and trades at $13.33, with analysts bullish (mean target $30.67) but primarily on the company's core burn/wound franchise rather than MW005 specifically.
How It Works
MW005 is a topical gel containing a concentrated mixture of protein-digesting enzymes (proteolytic enzymes) derived from pineapple stems, primarily bromelain. When applied directly to basal cell carcinoma lesions on the skin, these enzymes break down the proteins that make up the cancerous tissue, selectively removing it while preserving healthy surrounding skin. The drug is designed for patients to apply themselves at home as a non-surgical alternative to cutting out skin cancer lesions.
Trial Status
A Phase 1/2 open-label, multicenter, randomized trial in low-risk BCC completed with positive results announced July 2023. Patients received seven topical applications over 14 days; eight weeks later target lesions were surgically removed and assessed. The drug was safe, well-tolerated, and achieved complete clinical and histological clearance. An investigator-initiated Phase 2 trial for non-melanoma skin cancers (including BCC, squamous cell carcinoma, actinic keratosis) was also conducted at Soroka Medical Center in Israel, but no results have been publicly reported. No further clinical trials have been announced since.
The Two-Sided Case
Upcoming Catalysts
- No scheduled drug-specific catalyst for MW005 identified. The next company-wide event is Q3 2026 earnings on November 12, 2026, which may include pipeline updates.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
MediWound Ltd. 424B5 MDWD ·Originating report